Adjuvant Nivolumab Plus Ipilimumab Combination Does Not Improve RFS Over Nivolumab Alone in Patients with Stage IIIB-D or IV Melanoma
Findings from the CheckMate 915 study primary endpoints of recurrence-free survival in the all randomised population and in patients with tumour PD-L1 expression < 1%